Special Meeting of Shareholders to be held on November 16, 2021 at 10 a.m. ET
Posted: October 25, 2021 at 1:08 PM CDT|Update: 9 hours ago
BOSTON and MENLO PARK, California, 25 October 2021 / PRNewswire / – Khosla Ventures Acquisition Co. (Nasdaq: KVSA) (“KVSA”), a special purpose acquisition company sponsored by a subsidiary of Khosla Ventures, LLC (“Khosla Ventures”), announced today that the Special Meeting of Shareholders (“Special Meeting”) to vote on the approval and adoption of KVSA’s business combination agreement with Valo Health, LLC (“Valo Health”) and the wholly owned subsidiary exclusive to Valo Health, Valo Health, Inc. (“Valo”), will be held live on November 16, 2021 at 10:00 a.m.ET. Following the business combination, Valo will be a 100% subsidiary of KVSA. Valo Health is a technology company designed to transform the drug discovery and development process using human-centric data and artificial intelligence-based calculations.
Shareholders of record at the close of business on October 13, 2021 are entitled to vote at the Special Meeting. The business combination, if approved by KVSA shareholders, should be closed as soon as possible after the extraordinary meeting. Upon closing of the business combination, KVSA will change its name to Valo Health Holdings, Inc. (“New Valo”) and the shares of New Valo are expected to trade on the New York Stock Exchange under the symbol “VH”.
A definitive proxy statement and other relevant materials will be mailed to registered shareholders of KVSA at the close of business on October 13, 2021. Shareholders are encouraged to read the proxy statement and related materials. support in their entirety. Shareholders may also obtain free copies of the Proxy Circular and all relevant documents filed or to be filed with the United States Securities and Exchange Commission (“SEC”) by the KVSA (when they are available). available) through the website maintained by the SEC at http://www.sec.gov. Documents filed by KVSA with the SEC can also be obtained free of charge from the KVSA website at https://khoslaventuresacquisitionco.com/kvsa or by written request to: Khosla Ventures Acquisition Co., 2128 Sand Hill Road, Menlo Park, California, 94025.
KVSA shareholders are encouraged to submit their votes as soon as possible to ensure that they are represented at the Special Meeting. KVSA has engaged DF King & Co., Inc. (“DF King”) as proxy for the Extraordinary Meeting. Shareholders needing assistance in voting for their KVSA shares can contact DF King by calling (800) 487-4870, or banks and brokers can call collect at (212) 269-5550, or by sending an e-mail to [email protected]
On Valo Health
Valo Health is a technology company designed to transform the drug discovery and development process using human-centric data and artificial intelligence-based calculations. As a digital-native company, Valo Health aims to fully integrate human-centric data throughout the drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of changing drugs. life while simultaneously reducing cost, time and failure rate. . The company’s Opal IT platform™ is an integrated set of capabilities designed to turn data into valuable information that can accelerate discovery and enable Valo Health to advance a strong pipeline of programs in the areas of cardiovascular metabolism, oncology and neurodegenerative diseases. Founded by Flagship Pioneering and based in Boston, MA, Valo Health also has offices in Lexington, MA, San Francisco, California, Princeton, New Jersey, and in Branford, Connecticut. To learn more, visit www.valohealth.com.
KVSA is a specialized acquisition company sponsored by subsidiaries of Khosla Ventures. Khosla Ventures operates a series of venture capital funds that make early stage venture capital investments and provide strategic advice to entrepreneurs who create businesses of lasting significance. The company was founded in 2004 by Vinod Khosla, co-founder of Sun Microsystems. Khosla Ventures manages over $ 14 billion in assets and focuses on a wide range of industries including artificial intelligence, agriculture / food, consumer, business, financial services, healthcare, l space, sustainable energy, robotics, VR / AR and 3D printing. Collectively, Khosla Ventures’ investment portfolio has created nearly half a trillion dollars in market value.
This communication contains certain forward-looking statements within the meaning of federal securities laws regarding the proposed transaction between Valo, Valo Health and KVSA. These forward-looking statements are generally identified by the words “believe”, “plan”, “expect”, “anticipate”, “estimate”, “intend”, “the strategy”, “the future”, ” opportunity “,” plan, “” may “,” should “,” will “,” would “,” will “,” continue “,” will probably result “and similar expressions. Forward-looking statements are predictions, projections and other statements regarding future events that are based on current expectations and assumptions and, therefore, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements contained in this communication. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of KVSA’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Registration Statement on Form S- 4 and other documents filed by KVSA from time to time with the SEC. These filings identify and address other significant risks and uncertainties that could cause actual events and results to differ materially from those contained in forward-looking statements. Forward-looking statements speak only as of the date on which they are made. Readers are cautioned not to place undue reliance on forward-looking statements, and Valo, Valo Health, and KVSA assume no obligation and do not intend to update or revise any forward-looking statements, whether at the time of writing. following new information, future events or otherwise. Neither Valo, Valo Health nor KVSA guarantees that Valo, Valo Health or KVSA will meet their expectations.
Additional information and where to find it / Non-solicitation
In connection with the proposed transaction, KVSA has filed, and the SEC has declared effective, a registration statement on Form S-4 containing a proxy / prospectus. The proxy circular / prospectus will be sent to the shareholders of KVSA. KVSA will also file other documents relating to the proposed transaction with the SEC. Before making any voting decisions, investors and holders of KVSA securities are urged to read the Proxy Circular / Prospectus and all other relevant documents filed or to be filed with the SEC in connection with the proposed transaction as soon as they become available because they will contain important information on the proposed transaction. Investors and security holders will be able to obtain free copies of the Proxy Circular / Prospectus and all other relevant documents filed or to be filed with the SEC by KVSA through the website maintained by the SEC at the. ‘address www.sec.gov.
Participants in the solicitation
KVSA, Valo and Valo Health and their respective directors and officers may be considered participants in the proxy solicitation of KVSA shareholders in connection with the proposed transaction. Information about who may be considered to be participants in the Solicitation is set out in the documents filed by KVSA with the SEC. To the extent that KVSA’s holdings of securities have changed from the amounts printed in the KVSA registration statement on Form S-1, these changes have been or will be reflected on the change of ownership statements on Form 4 filed. with the SEC. A list of the names of such directors and officers and information regarding their interests in the business combination is contained in the proxy circular / prospectus. You can obtain free copies of these documents as described in the previous paragraph.
No offer or solicitation
These communications do not constitute an offer to sell or the solicitation of an offer to buy securities, nor a solicitation of a vote or approval, and there will be no sale of securities in any jurisdiction in which such an offer. , solicitation or sale would be illegal prior to registration or qualification under the securities laws of such jurisdiction. No offer of securities will be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.
Show original content:
SOURCE Khosla Ventures Acquisition Co.
The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.